HNDC Selected to Participate in Phase 3 Trial of Valbenazine
Update on RG6042 (formerly known as IONIS-HTTRx) Huntington’s disease global development programme: Two clinical studies to begin by end of 2018
Thank you for your ongoing support and interest in the investigational medicine RG6042 for Huntington’s disease (HD).
Over the past months we and our partner Ionis Pharmaceuticals have been heavily engaged with communities around the world (patient groups, medical professionals, Health Authorities and payers) to collaborate and build the RG6042 global development programme and upcoming studies. We are
eager for RG6042 to advance into further clinical development. In addition, as announced last month, the European Medicines Agency granted RG6042 PRIME (“PRIority MEdicine”) designation, which provides promising medicines enhanced interactions with the agency and the potential for accelerated evaluation.
‘I feel so much hope’—Is a new drug keeping this woman’s deadly Huntington disease at bay?
The dark shadow of Huntington disease fell squarely over Michelle Dardengo’s life on the day in 1986 that her 52-year-old father was found floating in the river in Tahsis, the remote Vancouver Island mill town where she grew up. Richard Varney had left his wedding ring, watch, and wallet on the bathroom counter; ridden his bike to a bridge that spans the rocky river; and jumped. The 4.5-meter drop broke his pelvis. The town doctor happened to be fishing below and pulled Varney out as he floated downstream, saving his life.